Suppr超能文献

溶酶体贮积症的基因治疗方法:新一代治疗方法。

Gene therapy approaches for lysosomal storage disease: next-generation treatment.

机构信息

Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, FL 32610, USA.

出版信息

Hum Gene Ther. 2012 Aug;23(8):808-15. doi: 10.1089/hum.2012.140.

Abstract

Lysosomal storage diseases are a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction. Multiple tissues ranging from musculoskeletal and visceral to tissues of the central nervous system are typically involved in disease pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Viral gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs. In this review, we discuss the various viral vector systems that have been developed and some of the strategy designs for the treatment of LSDs.

摘要

溶酶体贮积症是一组由于正常溶酶体功能缺陷引起的罕见的先天性代谢错误。这些疾病的特征是受影响细胞的溶酶体中储存物质的进行性积累,最终导致细胞功能障碍。从肌肉骨骼和内脏到中枢神经系统的多种组织通常都涉及疾病的病理过程。自从酶替代疗法 (ERT) 用于治疗某些 LSD 以来,总体临床结果有了显著改善;然而,输注蛋白的治疗是终身的,并且在患者中仍然明显存在持续的疾病进展。病毒基因治疗可能为 LSD 的现有管理策略提供可行的替代或辅助治疗方法。在这篇综述中,我们讨论了已经开发的各种病毒载体系统以及一些用于治疗 LSD 的策略设计。

相似文献

1
Gene therapy approaches for lysosomal storage disease: next-generation treatment.
Hum Gene Ther. 2012 Aug;23(8):808-15. doi: 10.1089/hum.2012.140.
2
Treatment of lysosomal storage diseases: recent patents and future strategies.
Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):9-25. doi: 10.2174/1872214808666140115111350.
3
Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I.
J Inherit Metab Dis. 2017 Jul;40(4):543-554. doi: 10.1007/s10545-017-0052-4. Epub 2017 May 30.
4
Lysosomal storage diseases: from pathophysiology to therapy.
Annu Rev Med. 2015;66:471-86. doi: 10.1146/annurev-med-122313-085916.
5
Advances in therapies for neurological lysosomal storage disorders.
J Inherit Metab Dis. 2023 Sep;46(5):874-905. doi: 10.1002/jimd.12615. Epub 2023 May 2.
6
Gene therapy for lysosomal storage disorders.
Expert Opin Biol Ther. 2001 Sep;1(5):857-67. doi: 10.1517/14712598.1.5.857.
7
New strategies for the treatment of lysosomal storage diseases (review).
Int J Mol Med. 2013 Jan;31(1):11-20. doi: 10.3892/ijmm.2012.1187. Epub 2012 Nov 19.
8
Recent developments in therapeutic approaches for lysosomal storage diseases.
Recent Pat CNS Drug Discov. 2011 Jan;6(1):1-19. doi: 10.2174/157488911794079127.
9
Gene therapy for lysosomal storage diseases (LSDs) in large animal models.
ILAR J. 2009;50(2):112-21. doi: 10.1093/ilar.50.2.112.
10
Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges.
Adv Exp Med Biol. 2021;1347:135-162. doi: 10.1007/5584_2021_639.

引用本文的文献

1
Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review.
Drug Deliv Transl Res. 2024 Oct;14(10):2615-2628. doi: 10.1007/s13346-024-01583-0. Epub 2024 Apr 8.
2
Gene therapy for neurotransmitter-related disorders.
J Inherit Metab Dis. 2024 Jan;47(1):176-191. doi: 10.1002/jimd.12697.
3
IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy.
Mol Ther Methods Clin Dev. 2022 Sep 24;27:109-130. doi: 10.1016/j.omtm.2022.09.010. eCollection 2022 Dec 8.
5
Advancements in AAV-mediated Gene Therapy for Pompe Disease.
J Neuromuscul Dis. 2020;7(1):15-31. doi: 10.3233/JND-190426.
6
Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
J Mol Med (Berl). 2017 Oct;95(10):1043-1052. doi: 10.1007/s00109-017-1562-0. Epub 2017 Jun 29.
7
Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.
Metab Brain Dis. 2017 Oct;32(5):1403-1415. doi: 10.1007/s11011-017-0009-1. Epub 2017 Apr 5.
9
Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.
Mol Ther. 2016 Dec;24(12):2054-2063. doi: 10.1038/mt.2016.181. Epub 2016 Sep 23.
10
Transcriptome assessment of the Pompe (Gaa-/-) mouse spinal cord indicates widespread neuropathology.
Physiol Genomics. 2016 Nov 1;48(11):785-794. doi: 10.1152/physiolgenomics.00075.2016. Epub 2016 Sep 9.

本文引用的文献

1
Retrograde gene delivery to hypoglossal motoneurons using adeno-associated virus serotype 9.
Hum Gene Ther Methods. 2012 Apr;23(2):148-56. doi: 10.1089/hgtb.2012.009.
2
Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII.
Mol Genet Metab. 2012 Jun;106(2):202-13. doi: 10.1016/j.ymgme.2012.03.022. Epub 2012 Apr 5.
3
The advent of AAV9 expands applications for brain and spinal cord gene delivery.
Expert Opin Biol Ther. 2012 Jun;12(6):757-66. doi: 10.1517/14712598.2012.681463. Epub 2012 Apr 20.
4
Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.
Mol Genet Metab. 2012 Sep;107(1-2):145-52. doi: 10.1016/j.ymgme.2012.03.013. Epub 2012 Mar 29.
5
Structural insight into the unique properties of adeno-associated virus serotype 9.
J Virol. 2012 Jun;86(12):6947-58. doi: 10.1128/JVI.07232-11. Epub 2012 Apr 11.
6
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
Hum Gene Ther. 2012 May;23(5):460-72. doi: 10.1089/hum.2011.063. Epub 2012 Mar 29.
7
Exploiting natural diversity of AAV for the design of vectors with novel properties.
Methods Mol Biol. 2011;807:93-118. doi: 10.1007/978-1-61779-370-7_4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验